Dec 18, 2023, 08:49 AM by

Dec 17, 2023, 19:03 PM by User Not Found

Bio-IT World | On Sunday, Illumina announced that the company will divest GRAIL.

Dec 15, 2023, 09:46 AM by

Research demonstrates the accuracy of Hyfe’s automated cough monitoring process and is the first to observe differences in type and length of cough between men and women.

Dec 15, 2023, 09:46 AM by

I just wanted to follow up to see if you had received my initial email regarding ReciBioPharm partners with Acuitas Therapeutics? Please let me know if there is any further information you require from me for this.

Dec 15, 2023, 09:46 AM by

Vergent Bioscience has enrolled the first patients in a Phase 2, multi-center study evaluating the efficacy and safety of VGT-309 in patients with cancer in the lung. Researchers at six sites in the U.S. and Australia will investigate the agent’s ability to help surgeons see tumors in real time during minimally invasive and robotic-assisted surgical procedures.

Dec 15, 2023, 09:46 AM by

Almaden Genomics has incorporated an end-to-end solution into g.nome™ to process, analyze, and visualize single-cell RNAseq data. A cloud-native platform designed for high-throughput sequencing data analysis, g.nome now includes features for alignment and quantification of gene expression per cell, Seurat clustering analysis, reference-based cell-type annotation, and built-in parallelization.

Dec 15, 2023, 09:46 AM by

Medical and consumer genetics testing innovator and Imperial College London spin-out, DnaNudge, today announces that it has received approval from Ghana’s Food and Drugs Authority (FDA) to deliver its breakthrough four-in-one, respiratory viruses test for clinical deployment both inside and outside labs in the West African country.

Dec 15, 2023, 01:00 AM by User Not Found

Bio-IT World | One of the major side effects of the massive increase in the use of artificial intelligence (AI) for basic research, translational research, clinical research, pharmaceutical development, and patient care is the tsunami of data that will be created.

Dec 14, 2023, 07:23 AM by

Qlucore, a leader in software development for precision cancer diagnostics, has taken a significant and crucial step towards obtaining a CE marked solution, initiating a formal performance evaluation study in Sweden and Denmark. Results from the study are expected early in 2024.

Dec 14, 2023, 07:23 AM by

Analyst firm, Frost & Sullivan today named AppOmni its Company of the Year for global SaaS Security Posture Management (SSPM) industry leadership. According to the report: “While many market participants are enhancing their SSPM solutions by increasing the number of SaaS applications being covered, the market still has an unmet need for an SSPM solution that provides consistent and comprehensive security coverage across core and custom SaaS applications. AppOmni addresses this market demand by offering its one-stop AppOmni Platform, which is the first SSPM solution in the market that enables customers to implement common security capabilities across their entire SaaS ecosystem.”

Dec 14, 2023, 07:23 AM by

I wanted to share some exciting insights from a joint report by Ashfield Event Experiences, part of Inizio Engage XD, and the International Pharmaceutical Congress Advisory Association (IPCAA). This report delves into the evolving landscape of healthcare provider (HCP) behaviors and attitudes towards medical congresses and conventions, particularly in the context of the return of in-person events. The full release is below.

Dec 13, 2023, 08:21 AM by

The industry growth include Increased government funding for life science technologies, growth of cell and gene therapies, rise in demand for biopharmaceuticals, technological advancements in life science tools, rise in the number of strategic deals & developments, and applications of genomic and proteomic technologies for precision medicine.

Dec 13, 2023, 08:02 AM by

Dec 13, 2023, 08:02 AM by

ome Biosciences, Inc., the programmable genomic integration company, has launched to usher in a new era of genomic medicines based on programmable genomic integration (PGI). PGI enables the insertion of any DNA sequence, of any size, into any programmed genomic location. The Company has raised $213 million in Series A and B funding from investors: Andreessen Horowitz (a16z) Bio + Health, ARCH Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, Alexandria Venture Investments and others.

Dec 13, 2023, 08:02 AM by

Avalon Announces Better Way for Health Insurance Plans to Manage Growth and Costs of Genetic Testing

Dec 13, 2023, 08:02 AM by

AI company transitions app to subscription model and adds exclusive new features for users in the UK, Canada, Europe and global users outside the U.S.

Dec 13, 2023, 01:00 AM by User Not Found

Bio-IT World | The development of antibiotics for treating tuberculosis in the 1940s eventually closed the doors of high-altitude sanitoriums that had long been the best therapeutic option for millions of patients. In much the same way, researchers at the Buck Institute for Research on Aging hope to one day eliminate the need to admit people suffering from Alzheimer’s, Parkinson’s disease, and other age-related phenomena to a geriatric or psychiatric hospital.

Dec 12, 2023, 08:43 AM by

Distributing real-world data to researchers in hours instead of days

Dec 12, 2023, 08:43 AM by

Carterra Inc. and ENPICOM B.V. announced today a collaboration to streamline the analysis of rapidly growing sequencing and antibody screening data generated in the lab.

Dec 12, 2023, 01:00 AM by User Not Found

Bio-IT World | The development of antibiotics for treating tuberculosis in the 1940s eventually closed the doors of high-altitude sanitoriums that had long been the best therapeutic option for millions of patients. In much the same way, researchers at the Buck Institute for Research on Aging hope to one day eliminate the need to admit people suffering from Alzheimer’s, Parkinson’s disease, and other age-related phenomena to a geriatric or psychiatric hospital.